{"entity":{"id":"yu-michael","kind":"person","name":"Michael Yu (Yu De-Chao)","aka":["De-Chao Yu","俞德超"],"tldr":"Michael Yu founded Innovent in Suzhou in 2011 and made sintilimab one of China's best-selling cancer drugs before turning the company into a supplier of new medicines to Roche and Takeda.","summary":"Yu earlier co-invented Oncorine (H101), the world's first approved oncolytic virus (China, 2005), and the anti-VEGF conbercept; at Innovent he built an integrated antibody company with sintilimab, four biosimilars, the CAR-T eque-cel partnership, KRAS G12C inhibitor fulzerasib and the IBI363 and IBI343 programmes licensed to Takeda in 2025.","asOf":"2026-09-10","links":[{"label":"Innovent Biologics","url":"https://www.innoventbio.com/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":["sintilimab","fulzerasib","equecabtagene-autoleucel"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder, Chairman and CEO, Innovent Biologics","specialisms":["Antibody therapeutics","Biotech leadership","Biosimilars"],"profiles":[{"label":"Innovent Biologics","url":"https://www.innoventbio.com/"}],"papers":[]},"route":"/people/yu-michael/","neighbours":{"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"drug":[{"id":"equecabtagene-autoleucel","kind":"drug","name":"Equecabtagene autoleucel","route":"/drugs/equecabtagene-autoleucel/"},{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}]}}